The Phase I Study of Propafenone, a New Antiarrhythmic Agent

A phase I study on propafenone hydrochloride (YM-13400), a new antiarrhythmic agent, was carried out in 12 healthy Japanese male volunteers . The safety, tolerance and pharmacokinetic profile of the drug were studied by single oral administration (group 1) and continuous administration (group 2). The six men of group 1 received 100, 200, and 300mg doses and the remaining six were given doses of 100 tid for 2 days, 200mg tid for 2days, and finally 200mg tid for 7days. Each dose were increased step by step at intervals of 2weeks or more after the safety of the drug was confirmed.No pronounced change was noted in vital signs (blood pressure, pulse rate), subjective symptoms, or clinical laboratory test data. Prolongation of PR, QRS and QTc interval was found at 2 to 4 hours after each administration.The maximum concentration (Cmax) and the area under the time-concentration curve (AUC) increased nonlinearly, increasing with each dosage. The biological half life in the elimination phase was about 2 to 3hours. In the continuous administration study, steady state was reached at about the 5 th day after administration. The amount of twenty-four hour cumulative urinary excretion of unchanged propafenone was 1% or less.The above results confirmed the safety of propafenone in healthy male volunteers.less.

[1]  H. Karagueuzian,et al.  Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed-chest dog: comparative study with lidocaine. , 1984, American heart journal.

[2]  G. Stiles,et al.  Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. , 1984, The Journal of pharmacology and experimental therapeutics.

[3]  S. Connolly,et al.  Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. , 1983, The American journal of cardiology.

[4]  S. Connolly,et al.  Clinical pharmacology of propafenone. , 1983, Circulation.

[5]  H. Karagueuzian,et al.  Suppression of Ventricular Arrhythmias by Propafenone, a New Antiarrhythmic Agent, During Acute Myocardial Infarction in the Conscious Dog A Comparative Study with Lidocaine , 1982, Circulation.

[6]  A. Mugelli,et al.  Electrophysiological and Antiarrhythmic Properties of Propafenon in Isolated Cardiac Preparations , 1981, Journal of cardiovascular pharmacology.

[7]  V. Legrand,et al.  Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. , 1981, European heart journal.

[8]  G. Breithardt,et al.  Propafenone--a new antiarrhythmic drug. , 1980, European heart journal.

[9]  K. Karsch,et al.  [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)]. , 1979, Deutsche medizinische Wochenschrift.

[10]  K. Keller,et al.  [Antiarrhythmic effect of propafenone in relation to serum concentration and conduction time (author's transl)]. , 1978, Zeitschrift für Kardiologie.

[11]  S. Higuchi,et al.  Determination of plasma protein binding of propafenone in rats, dogs and humans by highly sensitive gas chromatography-mass spectrometry. , 1985, Journal of chromatography.

[12]  P. Coumel,et al.  European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. , 1984, The American journal of cardiology.

[13]  E. Prystowsky,et al.  Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. , 1984, The American journal of cardiology.

[14]  D. Roden,et al.  Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. , 1984, The American journal of cardiology.

[15]  E. Prystowsky,et al.  Antiarrhythmic and electrophysiologic effects of oral propafenone. , 1984, The American journal of cardiology.

[16]  M. Kohlhardt Block of sodium currents by antiarrhythmic agents: analysis of the electrophysiologic effects of propafenone in heart muscle. , 1984, The American journal of cardiology.

[17]  M. Murphy,et al.  Effect of propafenone on left ventricular ejection fraction. , 1984, The American journal of cardiology.

[18]  D. Salerno,et al.  Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity. , 1984, The American journal of cardiology.

[19]  G. Breithardt,et al.  Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. , 1984, The American journal of cardiology.

[20]  R. Asinger,et al.  A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. , 1984, The American journal of cardiology.

[21]  M. Hollmann,et al.  Investigations on the pharmacokinetics of propafenone in man. , 1983, Arzneimittel-Forschung.

[22]  Williams,et al.  Classification of antiarrhythmic drugs , 1975 .

[23]  E. Vaughan-Williams Classification of antiarrhythmic drugs. , 1970 .